If you have been reading about certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
After prevailing, the player is transported to the Black Mesa staff dormitories, where he is witness to the G-Man's rescue of Alyx Vance. The player is then abandoned by the G-Man and presumably killed by a nuclear explosion that was set off. Candidate Twelve's file is closed due to his influence from the mysterious entity from earlier in the game.
=== Diaphragm === The diaphragm is an important part of the body's digestive system. The muscular diaphragm separates the thoracic cavity from the abdominal cavity where most of the digestive organs are located. The suspensory muscle attaches the ascending duodenum to the diaphragm. This muscle is thought to be of help in the digestive system in that its attachment offers a wider angle to the duodenojejunal flexure for the easier passage of digesting material. The diaphragm also attaches to, and anchors the liver at its bare area. The esophagus enters the abdomen through a hole in the diaphragm at the level of T10.
=== Neural circuit mechanism with PGE2 action === PGE2 release comes from the arachidonic acid pathway. This pathway (as it relates to fever), is mediated by the enzymes phospholipase A2 (PLA2), cyclooxygenase-2 (COX-2), and prostaglandin E2 synthase. These enzymes ultimately mediate the synthesis and release of PGE2. PGE2 is the ultimate mediator of the febrile response. The setpoint temperature of the body will remain elevated until PGE2 is no longer present. PGE2 acts on neurons in the preoptic area (POA) through the prostaglandin E receptor 3 (EP3). EP3-expressing neurons in the POA innervate the dorsomedial hypothalamus (DMH), the rostral raphe pallidus nucleus in the medulla oblongata (rRPa), and the paraventricular nucleus (PVN) of the hypothalamus. Under normal conditions, EP3-expressing neurons in the POA are important thermoregulatory neurons, which provide continuous inhibitory signals with the transmitter GABA to control sympathetic output neurons in the DMH and rRPa, thereby performing bidirectional regulation of basal body temperature. During infection, PGE2 produced in the brain inhibits the activity of EP3-expressing neurons in the POA to attenuate the inhibition of sympathetic output, and thereby activates the sympathetic output system, which evokes non-shivering thermogenesis to produce body heat and skin vasoconstriction to decrease heat loss from the body surface, leading to fever.
Sources: en.wikipedia.org
As anti-angiogenic cancer therapies have achieved widespread use, there has been increased interest in non-invasive monitoring of angiogenesis. One of the most extensively examined targets of angiogenesis is integrin αVβ3. Radiolabeled peptides containing RGD show high affinity and selectivity for integrin αVβ3 and are being investigated as tools to monitor treatment response of tumors via PET imaging. These include 18F-Galacto-RGD, 18F-Fluciclatide-RGD, 18F-RGD-K5, 68Ga-NOTA-RGD, 68Ga-NOTA-PRGD2, 18F-Alfatide, 18F-Alfatide II, and 18F-FPPRGD2. In a meta-analysis of studies using PET/CT in patients with cancer, it was shown that this diagnostic method may be very useful for detecting malignancies and predicting short-term outcomes, although larger-scale studies are needed.
=== Requests for a moratorium on military use === A number of anti-war activists specializing in international humanitarian law have questioned the legality of the continued use of depleted uranium weapons, highlighting that the effects may breach the principle of distinction (between civilians and military personnel). Some states and the International Coalition to Ban Uranium Weapons, a coalition of more than 155 non-governmental organizations, have asked for a ban on the production and military use of depleted uranium weapons. The European Parliament has repeatedly passed resolutions requesting an immediate moratorium on the further use of depleted uranium ammunition, but France and Britain – the only European states that are permanent members of the United Nations Security Council—have consistently rejected calls for a ban, maintaining that its use continues to be legal, and that the health risks are unsubstantiated. In 2007, France, Britain, the Netherlands, and the Czech Republic voted against a United Nations General Assembly resolution to hold a debate in 2009 about the effects of the use of armaments and ammunitions containing depleted uranium. All other European Union nations voted in favour or abstained.
=== Cardiac === The apelin receptor is expressed early during the embryonic development of the heart, where it regulates the migration of cell progenitors fated to differentiate into cardiomyocytes, the contractile cells of the heart. Its expression is also detected in the cardiomyocytes of the adult where apelin behaves as one of the most potent stimulator of cardiac contractility. Aged apelin knockout mice develop progressive impairment of cardiac contractility. Apelin acts as a mediator of the cardiovascular control, including for blood pressure and blood flow. It is one of the most potent stimulators of cardiac contractility yet identified, and plays a role in cardiac tissue remodeling. Apelin levels are increased in left ventricles of patients with chronic heart failure and also in patients with chronic liver disease.
General elections were held in East Germany on 18 March 1990. These were the first free elections held in the region since the turbulent Weimar days of 1932 and would become the only truly democratic vote in the German Democratic Republic (GDR). The election stood as a final verdict on four decades of one-party rule by the Socialist Unity Party of Germany (SED)–led National Front. It took place against the backdrop of the German reunification process, which had already begun to gather momentum. The contest was swept by the Alliance for Germany, a coalition led by the newly reconstituted East German Christian Democratic Union (CDU), which captured 192 of the 400 seats in the Volkskammer and had run on a promise of swift reunification with West Germany. The Social Democratic Party (SPD), re-established only months earlier after its forced 1946 merger with the Communist Party of Germany (KPD), was widely tipped to win but instead came second with 88 seats. In third was the former ruling SED, now rebranded as the Party of Democratic Socialism (PDS), which secured 66 seats. The Alliance fell just short of an outright majority having needed 201 seats to govern alone. Lothar de Maizière, the CDU's leader, invited the SPD to join a broad coalition alongside the German Social Union (DSU) and Democratic Awakening (DA). The SPD hesitated, wary of the DSU's right-wing populist tone, having earlier vowed to collaborate with all but the PDS and DSU. However, a grand coalition was ultimately formed.
Sources: en.wikipedia.org
On October 2, 2025, FIFA announced the video game FIFA Heroes, scheduled for release in 2026 on Android, iOS, Nintendo Switch, PlayStation, and Xbox platforms. In May 2026, the Football Manager 26 video game also announced the addition of licensed 2026 FIFA World Cup content. In December 2025, Netflix announced a new simulation-type game featuring the World Cup, produced by Delphi Interactive and Refactor Games. In May 2026, it was announced the Netflix-published game would be titled FIFA World Cup: Launch Edition; it was released in June 2026. In the same May 2026 announcement, FIFA also confirmed that they would adopt a non-exclusive "Digital Football" ecosystem, with games of various genres adopting the FIFA license. Alongside the new World Cup game were FIFA Heroes, FIFA Rivals, FIFA Super Soccer, Football Manager, eFootball and Rocket League, with more games joining the ecosystem in the following months.
== Research and career == In 2003, Cooper returned to the United Kingdom, where she was awarded a Wellcome Trust University Fellowship and joined the University of Birmingham. Cooper develops native ambient and ion mobility mass spectrometry to study protein structure a directly in the physiological environment (for example, in tissue). The large-scale study of proteins is known as proteomics. Cooper has shown that ambient mass spectrometry of proteins can provide the molecular-level sensitivity required to understand the processes that underpin disease, and can be used to inform the design of new pharmaceuticals. She has combined mass spectrometry with electron-capture dissociation and collision-induced dissociation. Cooper has studied the fragmentation processes and post-translational modifications of peptides. Such investigations are crucial to understand a range of biological processes. She is an associate editor of the Journal of the American Society for Mass Spectrometry.
=== Availability === Cyproheptadine is available widely throughout the world. This includes in Australia, Canada, Europe, Hong Kong, India, Japan, Mexico, Turkey, the United Kingdom, and the United States, among others.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.